Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Moderate Buy at Raymond James

Raymond James upgraded shares of Dianthus Therapeutics (NASDAQ:DNTH) to a moderate buy rating in a report released on Thursday morning,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Oppenheimer increased their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Stock Up 1.3 %

DNTH stock opened at $23.81 on Thursday. The business has a 50 day moving average of $26.09 and a 200-day moving average of $26.54. The firm has a market cap of $704.78 million, a PE ratio of -9.52 and a beta of 1.74. Dianthus Therapeutics has a 12-month low of $6.58 and a 12-month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, research analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its holdings in shares of Dianthus Therapeutics by 860.5% in the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock worth $2,095,000 after buying an additional 72,509 shares in the last quarter. HighVista Strategies LLC bought a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $542,000. SG Americas Securities LLC lifted its stake in Dianthus Therapeutics by 104.0% in the 3rd quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after purchasing an additional 4,506 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Dianthus Therapeutics by 151.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after purchasing an additional 263,500 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. grew its position in shares of Dianthus Therapeutics by 281.9% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company’s stock valued at $1,022,000 after purchasing an additional 29,159 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.